Immune Checkpoint Blockade

Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103⁺ conventional dendritic cells
Yifan Zhou, Natalie Slone, Taylor T Chrisikos, Oleksandr Kyrysyuk, Rachel L Babcock, Yusra B Medik, Haiyan S Li, Eugenie S Kleinerman, Stephanie S Watowich

Journal for ImmunoTherapy of Cancer Apr 2020, 8 (1) e000474; DOI: 10.1136/jitc-2019-000474
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
Abdul Rafeh Naqash, Danielle M. File, Carolyn M. Ziemer, Young E. Whang, Paula Landman, Paul B. Googe, Frances A. Collichio

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 4; DOI: 10.1186/s40425-018-0475-y
Exploring the emerging role of the microbiome in cancer immunotherapy
Jessica Fessler, Vyara Matson, Thomas F. Gajewski

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 108; DOI: 10.1186/s40425-019-0574-4
B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
William Damsky, Lucia Jilaveanu, Noel Turner, Curtis Perry, Christopher Zito, Mary Tomayko, Jonathan Leventhal, Kevan Herold, Eric Meffre, Marcus Bosenberg, Harriet M. Kluger

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 153; DOI: 10.1186/s40425-019-0613-1
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
Stefanie R. Mullins, John P. Vasilakos, Katharina Deschler, Iwen Grigsby, Pete Gillis, Julius John, Matthew J. Elder, John Swales, Elina Timosenko, Zachary Cooper, Simon J. Dovedi, Andrew J. Leishman, Nadia Luheshi, James Elvecrog, Ashenafi Tilahun, Richard Goodwin, Ronald Herbst, Mark A. Tomai, Robert W. Wilkinson

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 244; DOI: 10.1186/s40425-019-0724-8
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Wendy Mao, Ali Ghasemzadeh, Zachary T. Freeman, Aleksandar Obradovic, Matthew G. Chaimowitz, Thomas R. Nirschl, Emily McKiernan, Srinivasan Yegnasubramanian, Charles G. Drake

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 277; DOI: 10.1186/s40425-019-0758-y
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
Jonathan A. Trujillo, Jason J. Luke, Yuanyuan Zha, Jeremy P. Segal, Lauren L. Ritterhouse, Stefani Spranger, Karen Matijevich, Thomas F. Gajewski

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 295; DOI: 10.1186/s40425-019-0780-0
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery
Molly A. Taylor, Adina M. Hughes, Josephine Walton, Anna M. L. Coenen-Stass, Lukasz Magiera, Lorraine Mooney, Sigourney Bell, Anna D. Staniszewska, Linda C. Sandin, Simon T. Barry, Amanda Watkins, Larissa S. Carnevalli, Elizabeth L. Hardaker

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 328; DOI: 10.1186/s40425-019-0794-7
Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
Hao-Xiang Wu, Yan-Xing Chen, Zi-Xian Wang, Qi Zhao, Ming-Ming He, Ying-Nan Wang, Feng Wang, Rui-Hua Xu

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 264; DOI: 10.1186/s40425-019-0737-3
Immunotherapeutic approaches to ovarian cancer treatment
Cariad Chester, Oliver Dorigo, Jonathan S Berek, Holbrook Kohrt

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (1) 7; DOI: 10.1186/s40425-015-0051-7

Main menu

Immune Checkpoint Blockade

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immune Checkpoint Blockade

Pages